Zim Laboratories gets TGA GMP certification for Nagpur facility

Regulatory & Legal View source PDF Explain this filing

ZIMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.8%Reaction day

₹140.15

prior close

₹143.80

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+1.1% vs market

On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.4

10m

+0.9

15m

+1.2

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+1.8+0.7+1.1

Next day

-3.1-1.0-2.1

-6.9-3.6-3.3

-5.8-4.5-1.3

-10.1-6.8-3.3

-10.7-6.4-4.3

+1.7pendingpending

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zim Laboratories received Good Manufacturing Practice certification from Australia's Therapeutic Goods Administration (TGA) for its Kalmeshwar, Nagpur facility. Issued on 15 October 2026 after an April 2026 inspection, the certification covers non-sterile finished products including hard capsules, tablets, granules, powders, wafers and soluble films. It is valid until 21 June 2028. This enables the company to pursue manufacturing partnerships in Australia and strengthens its regulatory credentials across Rest of World markets.

Likely market impact

Positive: Unlocks Australian market entry and reinforces global manufacturing credentials, supporting future international partnerships and exports.